Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Carcinoma, Renal Cell 1

Interventions

valrubicin 1temsirolimus 1pembrolizumab 1palbociclib 1niraparib 1enfortumab vedotin 1cabozantinib 1atezolizumab 1Zoledronic Acid 1Valproic Acid 1VMBP protocol 1Trastuzumab 1Sunitinib 1Standard of Care 1Sirolimus 1Prednisone 1Nivolumab 1Mitomycin 1Immunoglobulin G 1Gemcitabine 1Etoposide 1Docetaxel 1Disulfides 1Cyclophosphamide 1Cisplatin 1Cetuximab 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urologic Neoplasms × VMBP protocol × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡